Loading clinical trials...

NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib | Clinical Trials | Clareo Health

COMPLETED

NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib

Non-Interventional Collecting Evidences For ILD in Taiwan: Optimized Novel Therapy

NCT04614441•Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

To better understand the clinical characteristics of Idiopathic Pulmonary Fibrosis (IPF) / Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)/ Progressive Fibrosing Interstitial Lung Disease (PF-ILD) patients treated with nintedanib and biomarkers associated with the disease course, a non-interventional, 3-year, prospective study will be conducted to collect the long-term real-world clinical data on IPF/SSc-ILD/PF-ILD patients newly administered with nintedanib in Taiwan

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•This study plans to enroll approximately 500 patients with IPF/SSc-ILD/PF-ILD who newly initiate nintedanib per physicians' discretion within 6 months before participating in the study.
•IPF cohort:
•Diagnosed with IPF during the prior 6 months before study enrollment, based on the 2018 ATS/ERS/JRS/ALAT guideline
•Patient ≥ 40 years of age
•Newly initiating nintedanib within 6 months prior to participating in the study
•Providing written informed consent prior to participating in the study
•Having further follow-up possibility with participating physician during the planned study period
•Ability to read and write in local language
•SSc-ILD cohort:
•Diagnosed with SSc-ILD during the prior 6 months before study enrollment, based on 2013 ACR/EULAR
+11 more criteria

Exclusion Criteria

•\- Lung transplantation expected within the next 6 months.
•-Included in ongoing interventional trials

Locations (26)

Chang-Hua Christian Hospital

Changhua, Taiwan

Chang Gung Memorial Hospital Chiayi

Chiayi City, Taiwan

National Taiwan University Hospital-Hsin-Chu Branch

Hsinchu, Taiwan

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, Taiwan

Kaohsiung Veterans General Hospital

Kaohsiung City, Taiwan

E-Da Hospital

Kaohsiung City, Taiwan

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, Taiwan

Taipei Tzu Chi General Hospital

New Taipei City, Taiwan

Taipei Medical University-Shuang Ho Hospital

New Taipei City, Taiwan

Chung Shan Medical University Hospital

Taichung, Taiwan

Key Dates

Start Date

January 21, 2021

Primary Completion Date

May 14, 2025

Completion Date

May 14, 2025

Last Updated

August 19, 2025

Enrollment

214

ACTUAL participants

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

OFEV®

DRUG

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622

Idiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis

View study

RECRUITINGPHASE3

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

NCT07299695

Idiopathic Pulmonary FibrosisAcute Exacerbation of Idiopathic Pulmonary Fibrosis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib

Inclusion Criteria

Exclusion Criteria

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males

Validation of the C-mo System - Cough Monitoring